Arcutis Biotherapeutics, Inc.
Arcutis Biotherapeutics, Inc. (ARQT) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
arqt · stock forecast · 12 analysts (3M) · FMP · updated Jun 8, 2026
Analyst Rating & Consensus
Based on 12 Wall Street analysts in the past 3 months
Buy
12 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$34.00
Consensus
$34.00
+57.8% upside
Low
$34.00
Median: $34 · Last Close: $21.54
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $21.70 | ↑ 0.76% |
1-day model range: $21.56–$21.85. Peak: $21.85 (+0.76%).
Long-Term Stock Price Prediction
Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | $24 | +10.5% |
| 2028 | $25 | +17.5% |
| 2029 | $26 | +22.0% |
| 2030 | $27 | +24.8% |
| 2031 | — | +26.5% |
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
NEUTRAL
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · ARQT · Jun 8, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-05-07 | Needham | Maintains | Buy→Buy |
| 2026-03-02 | Mizuho | Maintains | Outperform→Outperform |
| 2026-02-27 | Guggenheim | Maintains | Buy→Buy |
| 2026-02-26 | TD Cowen | Maintains | Buy→Buy |
| 2026-02-26 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2026-02-26 | Needham | Maintains | Buy→Buy |
| 2026-01-26 | Needham | Maintains | Buy→Buy |
| 2025-11-28 | Mizuho | Maintains | Outperform→Outperform |
| 2025-10-30 | Goldman Sachs | Maintains | Neutral→Neutral |
| 2025-10-28 | Needham | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on Arcutis Biotherapeutics, Inc. (ARQT) stock. Of the recent 75 rating actions, 3 were upgrades and 3 were downgrades. 12 analysts currently cover ARQT.
Analyst Recommendation Trends
ARQT analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 1 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$497M
↓ 36.5% YoY
Revenue Next Year
$646M
↑ 29.9% YoY
EPS This Year
$0.20
EPS Next Year
$1.07
↑ 436.9% YoY
EPS ForecastReported vs Estimated
Analysts forecast ARQT EPS of $0.20 for the current fiscal year, based on estimates from 4 analysts. The ARQT revenue forecast is $497M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The ARQT stock forecast is supported by two independent data sources: analyst consensus ratings from 12 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus ARQT price target is $34.00 (+57.8% upside), with an analyst consensus of Buy.
The ARQT short-term stock prediction for tomorrow is $21.70 (+0.76%). The ARQT stock price prediction for 2027 estimates an average of $24. The ARQT stock prediction for 2030 projects a range of $25–$29.
Arcutis Biotherapeutics, Inc. trades on NASDAQ under the ticker ARQT. The ARQT stock outlook for 2027 is broadly positive, supported by a Buy consensus among 83% of covering analysts.
Frequently asked questions
ARQT forecast · 8 questionsAccording to 12 Wall Street analysts, the average 12-month ARQT price target is $34.00, with a high forecast of $34.00 and a low of $34.00. The median price target is shown in the chart above when available. This implies +57.8% potential upside from the current price of $21.54.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.